Molecular Cancer Therapeutics: 12 (10)

Highlights

Highlights

Highlights of This Issue

Mol Cancer Ther October 1 2013 12 (10) 1923-1923;

Review

Review

RAC1: An Emerging Therapeutic Option for Targeting Cancer Angiogenesis and Metastasis

Hemant K. Bid, Ryan D. Roberts, Parmeet K. Manchanda and Peter J. Houghton

Mol Cancer Ther October 1 2013 12 (10) 1925-1934; DOI:10.1158/1535-7163.MCT-13-0164

Small Molecule Therapeutics

Small Molecule Therapeutics

Targeting Aberrant Sialylation in Cancer Cells Using a Fluorinated Sialic Acid Analog Impairs Adhesion, Migration, and In Vivo Tumor Growth

Christian Büll, Thomas J. Boltje, Melissa Wassink, Annemarie M.A. de Graaf, Floris L. van Delft, Martijn H. den Brok and Gosse J. Adema

Mol Cancer Ther October 1 2013 12 (10) 1935-1946; DOI:10.1158/1535-7163.MCT-13-0279
Small Molecule Therapeutics

Novel Inhibitors of Cyclin-Dependent Kinases Combat Hepatocellular Carcinoma without Inducing Chemoresistance

Christine Haider, Markus Grubinger, Eva Řezníčková, Thomas S. Weiss, Hans Rotheneder, Walter Miklos, Walter Berger, Radek Jorda, Marek Zatloukal, Tomáš Gucký, Miroslav Strnad, Vladimír Kryštof and Wolfgang Mikulits

Mol Cancer Ther October 1 2013 12 (10) 1947-1957; DOI:10.1158/1535-7163.MCT-13-0263
Small Molecule Therapeutics

Overcoming Platinum Resistance in Preclinical Models of Ovarian Cancer Using the Neddylation Inhibitor MLN4924

Amir A. Jazaeri, Etsuko Shibata, Jonghoon Park, Jennifer L. Bryant, Mark R. Conaway, Susan C. Modesitt, Peter G. Smith, Michael A. Milhollen, Allison J. Berger and Anindya Dutta

Mol Cancer Ther October 1 2013 12 (10) 1958-1967; DOI:10.1158/1535-7163.MCT-12-1028
Small Molecule Therapeutics

Combination Drug Scheduling Defines a “Window of Opportunity” for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900

Elizabeth Blackwood, Jennifer Epler, Ivana Yen, Michael Flagella, Tom O'Brien, Marie Evangelista, Stephen Schmidt, Yang Xiao, Jonathan Choi, Kaska Kowanetz, Judi Ramiscal, Kenton Wong, Diana Jakubiak, Sharon Yee, Gary Cain, Lewis Gazzard, Karen Williams, Jason Halladay, Peter K. Jackson and Shiva Malek

Mol Cancer Ther October 1 2013 12 (10) 1968-1980; DOI:10.1158/1535-7163.MCT-12-1218
Small Molecule Therapeutics

A Urokinase Receptor–Derived Peptide Inhibiting VEGF-Dependent Directional Migration and Vascular Sprouting

Katia Bifulco, Immacolata Longanesi-Cattani, Eleonora Liguori, Claudio Arra, Domenica Rea, Maria Teresa Masucci, Mario De Rosa, Vincenzo Pavone, Maria Patrizia Stoppelli and Maria Vincenza Carriero

Mol Cancer Ther October 1 2013 12 (10) 1981-1993; DOI:10.1158/1535-7163.MCT-13-0077
Small Molecule Therapeutics

The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas

Ryan T. Anderson, Stephen B. Keysar, Daniel W. Bowles, Magdalena J. Glogowska, David P. Astling, J. Jason Morton, Phuong Le, Adrian Umpierrez, Justin Eagles-Soukup, Gregory N. Gan, Brian W. Vogler, Daniel Sehrt, Sarah M. Takimoto, Dara L. Aisner, Francois Wilhelm, Barbara A. Frederick, Marileila Varella-Garcia, Aik-Choon Tan and Antonio Jimeno

Mol Cancer Ther October 1 2013 12 (10) 1994-2005; DOI:10.1158/1535-7163.MCT-13-0206
Small Molecule Therapeutics

Novel Treatment for Mantle Cell Lymphoma Including Therapy-Resistant Tumor by NF-κB and mTOR Dual-Targeting Approach

Nagendra K. Chaturvedi, Rajkumar N. Rajule, Ashima Shukla, Prakash Radhakrishnan, Gordon L. Todd, Amarnath Natarajan, Julie M. Vose and Shantaram S. Joshi

Mol Cancer Ther October 1 2013 12 (10) 2006-2017; DOI:10.1158/1535-7163.MCT-13-0239
Small Molecule Therapeutics

Sunitinib and SU11652 Inhibit Acid Sphingomyelinase, Destabilize Lysosomes, and Inhibit Multidrug Resistance

Anne-Marie Ellegaard, Line Groth-Pedersen, Viola Oorschot, Judith Klumperman, Thomas Kirkegaard, Jesper Nylandsted and Marja Jäättelä

Mol Cancer Ther October 1 2013 12 (10) 2018-2030; DOI:10.1158/1535-7163.MCT-13-0084

Large Molecule Therapeutics

Large Molecule Therapeutics | AuthorChoice

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models

Sylvia Herter, Frank Herting, Olaf Mundigl, Inja Waldhauer, Tina Weinzierl, Tanja Fauti, Gunter Muth, Doris Ziegler-Landesberger, Erwin Van Puijenbroek, Sabine Lang, Minh Ngoc Duong, Lina Reslan, Christian A. Gerdes, Thomas Friess, Ute Baer, Helmut Burtscher, Michael Weidner, Charles Dumontet, Pablo Umana, Gerhard Niederfellner, Marina Bacac and Christian Klein

Mol Cancer Ther October 1 2013 12 (10) 2031-2042; DOI:10.1158/1535-7163.MCT-12-1182
Large Molecule Therapeutics | AuthorChoice

Targeting Aberrant DNA Double-Strand Break Repair in Triple-Negative Breast Cancer with Alpha-Particle Emitter Radiolabeled Anti-EGFR Antibody

Hong Song, Mohammad Hedayati, Robert F. Hobbs, Chunbo Shao, Frank Bruchertseifer, Alfred Morgenstern, Theodore L. DeWeese and George Sgouros

Mol Cancer Ther October 1 2013 12 (10) 2043-2054; DOI:10.1158/1535-7163.MCT-13-0108
Large Molecule Therapeutics

The Functionalized Human Serine Protease Granzyme B/VEGF₁₂₁ Targets Tumor Vasculature and Ablates Tumor Growth

Khalid A. Mohamedali, Yu Cao, Lawrence H. Cheung, Walter N. Hittelman and Michael G. Rosenblum

Mol Cancer Ther October 1 2013 12 (10) 2055-2066; DOI:10.1158/1535-7163.MCT-13-0165

Cancer Therapeutics Insights

Cancer Therapeutics Insights

Berbamine Inhibits the Growth of Liver Cancer Cells and Cancer-Initiating Cells by Targeting Ca²⁺/Calmodulin-Dependent Protein Kinase II

Zhipeng Meng, Tao Li, Xiaoxiao Ma, Xiaoqiong Wang, Carl Van Ness, Yichao Gan, Hong Zhou, Jinfen Tang, Guiyu Lou, Yafan Wang, Jun Wu, Yun Yen, Rongzhen Xu and Wendong Huang

Mol Cancer Ther October 1 2013 12 (10) 2067-2077; DOI:10.1158/1535-7163.MCT-13-0314
Cancer Therapeutics Insights

Histone Deacetylase Regulation of ATM-Mediated DNA Damage Signaling

K. Ted Thurn, Scott Thomas, Paromita Raha, Ian Qureshi and Pamela N. Munster

Mol Cancer Ther October 1 2013 12 (10) 2078-2087; DOI:10.1158/1535-7163.MCT-12-1242
Cancer Therapeutics Insights

Histone Deacetylase Inhibition Overcomes Drug Resistance through a miRNA-Dependent Mechanism

Tracy Murray-Stewart, Christin L. Hanigan, Patrick M. Woster, Laurence J. Marton and Robert A. Casero Jr

Mol Cancer Ther October 1 2013 12 (10) 2088-2099; DOI:10.1158/1535-7163.MCT-13-0418
Cancer Therapeutics Insights

PI3K Stimulates DNA Synthesis and Cell-Cycle Progression via Its p55PIK Regulatory Subunit Interaction with PCNA

Guihua Wang, Xiaonian Cao, Senyan Lai, Xuelai Luo, Yongdong Feng, Xianmin Xia, Paul M. Yen, Jianping Gong and Junbo Hu

Mol Cancer Ther October 1 2013 12 (10) 2100-2109; DOI:10.1158/1535-7163.MCT-12-0920
Cancer Therapeutics Insights

Catalase Abrogates β-Lapachone–Induced PARP1 Hyperactivation–Directed Programmed Necrosis in NQO1-Positive Breast Cancers

Erik A. Bey, Kathryn E. Reinicke, Melissa C. Srougi, Marie Varnes, Vernon E. Anderson, John J. Pink, Long Shan Li, Malina Patel, Lifen Cao, Zachary Moore, Amy Rommel, Michael Boatman, Cheryl Lewis, David M. Euhus, William G. Bornmann, Donald J. Buchsbaum, Douglas R. Spitz, Jinming Gao and David A. Boothman

Mol Cancer Ther October 1 2013 12 (10) 2110-2120; DOI:10.1158/1535-7163.MCT-12-0962
Cancer Therapeutics Insights

Sorafenib Overcomes Irinotecan Resistance in Colorectal Cancer by Inhibiting the ABCG2 Drug-Efflux Pump

Thibault Mazard, Annick Causse, Joelle Simony, Wilhem Leconet, Nadia Vezzio-Vie, Adeline Torro, Marta Jarlier, Alexandre Evrard, Maguy Del Rio, Eric Assenat, Pierre Martineau, Marc Ychou, Bruno Robert and Celine Gongora

Mol Cancer Ther October 1 2013 12 (10) 2121-2134; DOI:10.1158/1535-7163.MCT-12-0966
Cancer Therapeutics Insights

Synthetic Lethal Targeting of PTEN-Deficient Cancer Cells Using Selective Disruption of Polynucleotide Kinase/Phosphatase

Todd R. Mereniuk, Mohamed A.M. El Gendy, Ana M. Mendes-Pereira, Christopher J. Lord, Sunita Ghosh, Edan Foley, Alan Ashworth and Michael Weinfeld

Mol Cancer Ther October 1 2013 12 (10) 2135-2144; DOI:10.1158/1535-7163.MCT-12-1093
Cancer Therapeutics Insights

Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation

Sun Mi Kim, Mi Ran Yun, Yun Kyoung Hong, Flavio Solca, Joo-Hang Kim, Hyun-Jung Kim and Byoung Chul Cho

Mol Cancer Ther October 1 2013 12 (10) 2145-2156; DOI:10.1158/1535-7163.MCT-12-1188
Cancer Therapeutics Insights

Overexpression of Asparagine Synthetase and Matrix Metalloproteinase 19 Confers Cisplatin Sensitivity in Nasopharyngeal Carcinoma Cells

Ran-Yi Liu, Zizheng Dong, Jianguo Liu, Ling Zhou, Wenlin Huang, Sok Kean Khoo, Zhongfa Zhang, David Petillo, Bin Tean Teh, Chao-Nan Qian and Jian-Ting Zhang

Mol Cancer Ther October 1 2013 12 (10) 2157-2166; DOI:10.1158/1535-7163.MCT-12-1190
Cancer Therapeutics Insights

Combining Erlotinib and Cetuximab Is Associated with Activity in Patients with Non–Small Cell Lung Cancer (Including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutations

Jennifer J. Wheler, Apostolia M. Tsimberidou, Gerald S. Falchook, Ralph G. Zinner, David S. Hong, Jansina Y. Fok, Siqing Fu, Sarina A. Piha-Paul, Aung Naing and Razelle Kurzrock

Mol Cancer Ther October 1 2013 12 (10) 2167-2175; DOI:10.1158/1535-7163.MCT-12-1208
Cancer Therapeutics Insights

EGFR Inhibition Promotes an Aggressive Invasion Pattern Mediated by Mesenchymal-like Tumor Cells within Squamous Cell Carcinomas

Devraj Basu, Arnaud F. Bewley, Steven M. Sperry, Kathleen T. Montone, Phyllis A. Gimotty, Kati Rasanen, Nicole D. Facompre, Gregory S. Weinstein, Hiroshi Nakagawa, J. Alan Diehl, Anil K. Rustgi and Meenhard Herlyn

Mol Cancer Ther October 1 2013 12 (10) 2176-2186; DOI:10.1158/1535-7163.MCT-12-1210
Cancer Therapeutics Insights

Cetuximab Reverses the Warburg Effect by Inhibiting HIF-1–Regulated LDH-A

Haiquan Lu, Xinqun Li, Zhongguang Luo, Jie Liu and Zhen Fan

Mol Cancer Ther October 1 2013 12 (10) 2187-2199; DOI:10.1158/1535-7163.MCT-12-1245
Cancer Therapeutics Insights

Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer

Rui Li, Zhongliang Hu, Shi-Yong Sun, Zhuo G. Chen, Taofeek K. Owonikoko, Gabriel L. Sica, Suresh S. Ramalingam, Walter J. Curran, Fadlo R. Khuri and Xingming Deng

Mol Cancer Ther October 1 2013 12 (10) 2200-2212; DOI:10.1158/1535-7163.MCT-13-0095
Cancer Therapeutics Insights

Subtype-Specific MEK-PI3 Kinase Feedback as a Therapeutic Target in Pancreatic Adenocarcinoma

Olga K. Mirzoeva, Eric A. Collisson, Peter M. Schaefer, Byron Hann, Yun K. Hom, Andrew H. Ko and W. Michael Korn

Mol Cancer Ther October 1 2013 12 (10) 2213-2225; DOI:10.1158/1535-7163.MCT-13-0104
Cancer Therapeutics Insights

Differential Induction of Apoptosis and Senescence by the DNA Methyltransferase Inhibitors 5-Azacytidine and 5-Aza-2′-Deoxycytidine in Solid Tumor Cells

Sascha Venturelli, Alexander Berger, Timo Weiland, Frank Essmann, Michaela Waibel, Tina Nuebling, Sabine Häcker, Martin Schenk, Klaus Schulze-Osthoff, Helmut R. Salih, Simone Fulda, Bence Sipos, Ricky W. Johnstone, Ulrich M. Lauer and Michael Bitzer

Mol Cancer Ther October 1 2013 12 (10) 2226-2236; DOI:10.1158/1535-7163.MCT-13-0137
Cancer Therapeutics Insights

Chemotherapy Counteracts Metastatic Dissemination Induced by Antiangiogenic Treatment in Mice

Alessandra Rovida, Vittoria Castiglioni, Alessandra Decio, Valentina Scarlato, Eugenio Scanziani, Raffaella Giavazzi and Marta Cesca

Mol Cancer Ther October 1 2013 12 (10) 2237-2247; DOI:10.1158/1535-7163.MCT-13-0244

Companion Diagnostics and Biomarkers

Companion Diagnostics and Biomarkers | AuthorChoice

Uracil–DNA Glycosylase Expression Determines Human Lung Cancer Cell Sensitivity to Pemetrexed

Lachelle D. Weeks, Pingfu Fu and Stanton L. Gerson

Mol Cancer Ther October 1 2013 12 (10) 2248-2260; DOI:10.1158/1535-7163.MCT-13-0172
Companion Diagnostics and Biomarkers | AuthorChoice

Prognostic Role of Lemur Tyrosine Kinase-3 Germline Polymorphisms in Adjuvant Gastric Cancer in Japan and the United States

Takeru Wakatsuki, Melissa J. LaBonte, Pierre O. Bohanes, Wu Zhang, Dongyun Yang, Mizutomo Azuma, Afsaneh Barzi, Yan Ning, Fotios Loupakis, Siamak Saadat, Nico Volz, Sebastian Stintzing, Rita El-Khoueiry, Wasaburo Koizumi, Masahiko Watanabe, Manish Shah, Justin Stebbing, Georgios Giamas and Heinz-Josef Lenz

Mol Cancer Ther October 1 2013 12 (10) 2261-2272; DOI:10.1158/1535-7163.MCT-12-1134

Tools and Technologies

Tools and Technologies

Receptor-Directed Chimeric Toxins Created by Sortase-Mediated Protein Fusion

Andrew J. McCluskey and R. John Collier

Mol Cancer Ther October 1 2013 12 (10) 2273-2281; DOI:10.1158/1535-7163.MCT-13-0358

Correction

Correction

Correction: Inhibition of Monocarboxylate Transporter 2 Induces Senescence-Associated Mitochondrial Dysfunction and Suppresses Progression of Colorectal Malignancies In Vivo

Mol Cancer Ther October 1 2013 12 (10) 2282-2282; DOI:10.1158/1535-7163.MCT-13-0727

Main menu

User menu

Search

Table of Contents

Highlights

Review

Small Molecule Therapeutics

Large Molecule Therapeutics

Cancer Therapeutics Insights

Companion Diagnostics and Biomarkers

Tools and Technologies

Correction

Issue Highlights

Jump to

Articles

Info for

About MCT